Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Corcept Therapeutics Inc.

Headquarters: Menlo Park, CA, United States of America
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Joseph K. Belanoff, MD
Number Of Employees: 500
Enterprise Value: $5,341,859,200
PE Ratio: 44.48
Exchange/Ticker 1: NASDAQ:CORT
Exchange/Ticker 2: N/A
Latest Market Cap: $5,786,840,064

BioCentury | Dec 18, 2024
Product Development

Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report

Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | May 30, 2024
Product Development

Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data

Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena
BioCentury | Dec 1, 2021
Management Tracks

Grauer becomes CMO at Federation Bio

Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more
BioCentury | Nov 19, 2021
Data Byte

New mechanisms enter the Cushing disease pipeline

The fourth disease-modifying therapy is nearing the market
BioCentury | Jul 13, 2021
Management Tracks

Berkley joins AbCellera as CBO; plus Genespire, Corcept, Shoreline and more

Antibody discovery company AbCellera Biologics Inc. (NASDAQ:ABCL) hired Neil Berkley as CBO.  Berkley joins from Halozyme Therapeutics Inc. (NASDAQ:HALO) where he was VP, head of business
BioCentury | Mar 4, 2021
Management Tracks

Amazon exec Lathia joins Flagship-backed Valo as chief product officer; plus AavantiBio, CatalYm, Corcept, Vincerx, OnCusp and more

Flagship-backed cloud computing-based drug discovery and development company Valo Health LLC named Nish Lathia chief product officer. The 18-year veteran of Amazon.com Inc. (NASDAQ:AMZN) held a
BioCentury | Nov 19, 2018
Company News

Management tracks: Brickell, Genevant

BioCentury | Apr 11, 2017
Distillery Therapeutics

Infectious disease

BioCentury | May 16, 2016
Clinical News

CORT125134: Phase I/II started

BioCentury | Dec 21, 2015
Clinical News

Mifepristone: Additional Phase I/II data

Items per page:
1 - 10 of 122